Abstract：
Several trials have evaluated the effects of folate supplementation on obesity indices. However, their results were inconsistent. Therefore, the current meta-analysis was conducted to summarize data from available randomized clinical trials (RCTs) about the impact of folate supplementation on weight and body mass index (BMI).
Medline/PubMed, Scopus, Embase, and ISI web of science were searched to identify relevant articles up to December 2020. The effect sizes were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI) using the random-effects model.
Pooled data from nine studies showed that folic acid supplementation did not change body weight (WMD: -0.16 kg, 95%CI: -0.47 to 0.16, P = 0.32) and BMI (WMD: -0.23 kg/m2, 95%CI: -0.49 to 0.03, P = 0.31), but there was significant heterogeneity between the included studies for BMI (I2 = 90.1%, P < 0.001). Moreover, subgroup analyses in level of homocysteine and health status indicated significant effect of folic acid supplementation on BMI in those with homocysteine level ≥15 μmol/L (WMD: -0.17 kg/cm2, -0.33 to -0.01, p = 0.03) and in women with polycystic ovary syndrome (PCOS) (WMD: - 0.30kg/cm2, -0.54 to -0.06, p = 0.01).
Our outcomes demonstrated that folic acid improves BMI in those with homocysteine levels ≥15 μmol/L and women with PCOS.
Medline/PubMed, Scopus, Embase, and ISI web of science were searched to identify relevant articles up to December 2020. The effect sizes were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI) using the random-effects model.
Pooled data from nine studies showed that folic acid supplementation did not change body weight (WMD: -0.16 kg, 95%CI: -0.47 to 0.16, P = 0.32) and BMI (WMD: -0.23 kg/m2, 95%CI: -0.49 to 0.03, P = 0.31), but there was significant heterogeneity between the included studies for BMI (I2 = 90.1%, P < 0.001). Moreover, subgroup analyses in level of homocysteine and health status indicated significant effect of folic acid supplementation on BMI in those with homocysteine level ≥15 μmol/L (WMD: -0.17 kg/cm2, -0.33 to -0.01, p = 0.03) and in women with polycystic ovary syndrome (PCOS) (WMD: - 0.30kg/cm2, -0.54 to -0.06, p = 0.01).
Our outcomes demonstrated that folic acid improves BMI in those with homocysteine levels ≥15 μmol/L and women with PCOS.
摘要：
目的：一些试验已经评估了补充叶酸对肥胖指数的影响。然而,他们的结果不一致。因此,本研究的荟萃分析旨在总结现有随机临床试验(RCT)中有关补充叶酸对体重和体重指数(BMI)影响的数据.
方法：Medline/PubMed，Scopus,Embase,和ISI科学网进行了搜索，以确定截至2020年12月的相关文章。使用随机效应模型将效应大小表示为加权平均差(WMD)和95%置信区间(CI)。
结果：来自9项研究的汇总数据表明，补充叶酸不会改变体重（WMD：-0.16kg，95CI：-0.47至0.16，P=0.32）和BMI（WMD：-0.23kg/m2，95CI：-0.49至0.03，P=0.31），但纳入的BMI研究之间存在显著异质性(I2=90.1%，P<0.001)。此外，对同型半胱氨酸水平和健康状况的亚组分析表明，在同型半胱氨酸水平≥15μmol/L的患者（WMD：-0.17kg/cm2，-0.33至-0.01，p=0.03）中，补充叶酸对BMI有显着影响。多囊卵巢综合征（PCOS）（WMD：-0.30kg/cm2，-0.54至-0.06，p=0.01）。
结论：我们的结果表明，叶酸可以改善同型半胱氨酸水平≥15μmol/L的患者和PCOS女性的BMI。
方法：Medline/PubMed，Scopus,Embase,和ISI科学网进行了搜索，以确定截至2020年12月的相关文章。使用随机效应模型将效应大小表示为加权平均差(WMD)和95%置信区间(CI)。
结果：来自9项研究的汇总数据表明，补充叶酸不会改变体重（WMD：-0.16kg，95CI：-0.47至0.16，P=0.32）和BMI（WMD：-0.23kg/m2，95CI：-0.49至0.03，P=0.31），但纳入的BMI研究之间存在显著异质性(I2=90.1%，P<0.001)。此外，对同型半胱氨酸水平和健康状况的亚组分析表明，在同型半胱氨酸水平≥15μmol/L的患者（WMD：-0.17kg/cm2，-0.33至-0.01，p=0.03）中，补充叶酸对BMI有显着影响。多囊卵巢综合征（PCOS）（WMD：-0.30kg/cm2，-0.54至-0.06，p=0.01）。
结论：我们的结果表明，叶酸可以改善同型半胱氨酸水平≥15μmol/L的患者和PCOS女性的BMI。
